Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance
Sanofi (SASY) reported Q3 earnings of €3.55 per share, exceeding estimates of €2.79. Sales rose 16.2% to €14.44B, driven by Dupixent's 35% sales increase to €5.7B. New drugs' sales grew 31.4%, offsetting a 6.6% vaccine sales decline. Sanofi raised FY guidance, expecting low-teens sales growth and mid-teens EPS growth.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest a short‑term upside for the stock, but long‑term risk remains around Dupixent patent expiry.
Market read
First‑report earnings beat with guidance lift for a large-cap pharma, likely to move the stock and sector.
What to watch
Potential loss of exclusivity on Dupixent in the next decade could pressure future earnings.
Background
Sanofi SA is a French multinational pharmaceutical company with a significant biologics portfolio.
Ticker impact
Sanofi reported Q3 earnings that beat estimates and raised FY sales and EPS guidance.
upward as the market prices in the earnings beat and higher guidance
Robust Dupixent sales drove a 22% YoY EPS increase and prompted a low‑teens sales growth outlook, which typically lifts the stock.
Market effects
Strengthens the pharma sector outlook, especially companies with high‑margin biologics.
Boosts European market sentiment, particularly French equities.
Adds to global biotech rally as investors seek exposure to high‑growth drugs.
Counterpoint
If Dupixent faces upcoming competition, the guidance hike may be overly optimistic.
Key entities
- companySanofi SA
French pharmaceutical giant reporting Q3 results.
- productDupixent
Key biologic driving earnings growth.
